21 Oct 2015 09:52
ABZENA PLC
("Abzena" or the "Group")
Appointment of Joint Broker
Cambridge, UK, 21 October 2015 - Abzena plc (AIM: ABZA), a life sciences Group providing services and technologies that enable the development and manufacture of biopharmaceutical products, has appointed N+1 Singer as joint broker with immediate effect. Cenkos Securities remains the Group's Nominated Adviser and joint broker.
-Ends-
For further information:
Abzena plc John Burt, Chief Executive Officer Julian Smith, Chief Financial Officer
| +44 1223 903 498 john.burt@abzena.com julian.smith@abzena.com
|
Cenkos Securities (Nominated Adviser and Broker) Christopher Golden / Ivonne Cantu
| +44 20 7397 8900
|
N+1 Singer (Joint Broker) Aubrey Powell / Liz Yong
| +44 20 7496 3000 |
Instinctif Partners MelanieToyne-Sewell / Rozi Morris
| +44 20 7457 2020 abzena@instinctif.com |
About Abzena
Abzena provides proprietary technologies and complementary services in the UK and US to enable the development and manufacture of biopharmaceuticals.
The Group comprises Antitope, PolyTherics and PacificGMP, which between them have built a global customer base including the majority of the top 20 biopharmaceutical companies as well as large and small biotech companies and academic groups.
Antitope provides immunogenicity assessment, protein engineering to create humanized antibodies and deimmunised therapeutic proteins, and cell line development for manufacture.
PacificGMP provides contract process development and manufacture of biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and gene therapy and cell therapy products, for preclinical and clinical studies.
PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimizing the therapeutic properties of biopharmaceuticals.
Abzena (AIM: ABZA) has its main operations in Cambridge, UK and in San Diego, CA, USA. For more information, please see www.abzena.com.